GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharos IBio Co Ltd (XKRX:388870) » Definitions » Net Current Asset Value

Pharos IBio Co (XKRX:388870) Net Current Asset Value : ₩1,723.53 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Pharos IBio Co Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Pharos IBio Co's net current asset value per share for the quarter that ended in Mar. 2024 was ₩1,723.53.

The historical rank and industry rank for Pharos IBio Co's Net Current Asset Value or its related term are showing as below:

XKRX:388870' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 6.67   Med: 7.72   Max: 10.87
Current: 7.44

During the past 5 years, the highest Price-to-Net-Current-Asset-Value Ratio of Pharos IBio Co was 10.87. The lowest was 6.67. And the median was 7.72.

XKRX:388870's Price-to-Net-Current-Asset-Value is ranked worse than
70.5% of 1027 companies
in the Biotechnology industry
Industry Median: 3.94 vs XKRX:388870: 7.44

Pharos IBio Co Net Current Asset Value Historical Data

The historical data trend for Pharos IBio Co's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharos IBio Co Net Current Asset Value Chart

Pharos IBio Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net Current Asset Value
-1,490.98 -3,806.19 -9,348.15 1,650.42 1,921.93

Pharos IBio Co Quarterly Data
Mar22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Net Current Asset Value Get a 7-Day Free Trial 1,274.37 1,002.92 2,112.70 1,921.93 1,723.53

Competitive Comparison of Pharos IBio Co's Net Current Asset Value

For the Biotechnology subindustry, Pharos IBio Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharos IBio Co's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharos IBio Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Pharos IBio Co's Price-to-Net-Current-Asset-Value falls into.



Pharos IBio Co Net Current Asset Value Calculation

Pharos IBio Co's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(A: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(26170.432-1341.046-0-0)/12.919
=1,921.93

Pharos IBio Co's Net Current Asset Value (NCAV) per share for the quarter that ended in Mar. 2024 is calculated as

Net Current Asset Value Per Share(Q: Mar. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(23398.132-1131.91-0-0)/12.919
=1,723.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharos IBio Co  (XKRX:388870) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Pharos IBio Co Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Pharos IBio Co's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharos IBio Co (XKRX:388870) Business Description

Traded in Other Exchanges
N/A
Address
427beon-gil, Dongan-gu, 1407 and 1408, 38, Heungan-daero, Seongji Star With, Gyeonggi-do, Gwanyang-dong, Anyang-si, KOR
Pharos IBio Co Ltd is a company specializing in new drug development that develops treatments for rare and intractable diseases. It utilizes a new drug development platform based on big data and AI technology. Its product candidate comprises PHI-101-AML, a treatment drug for refractory/relapsed acute myeloid leukemia; PHI-101-OC developed for platinum-resistant/refractory ovarian cancer patients; PHI-101-TNBC is being developed as a drug to treat metastatic triple-negative breast cancer (TNBC); PHI-201; PHI-301; and PHI-501.

Pharos IBio Co (XKRX:388870) Headlines

No Headlines